COMPARISON
Calcitonin vs Teriparatide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Calcitonin is authorised or registered in 8 and Teriparatide in 10 of the 10 registers read. Calcitonin: highest phase Phase 4 (after approval). Teriparatide: highest phase Phase 4 (after approval). 5 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Calcitonin | Teriparatide | |
|---|---|---|
| Registered trials differs | 154 clinicaltrials.gov · 2026-10-03 | 185 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: CALCITONIN SALMON openfda · 2026-10-03T17:23:44.062Z | FDA-approved: teriparatide openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for calcitonin | 2003-06-10 ema · 2026-10-03 |
| EU withdrawn on differs | 2008-11-20 ema · 2026-10-03 | 2020-11-24 ema · 2026-10-03 |
| ATC code differs | H05BA01 ema · 2026-10-03 | H05AA02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Calcitonin | placebo | Teriparatide | placebo |
|---|---|---|---|---|
| Arthralgia | 16.5% | 21.9% | 9.1% | 9.2% |
| Nausea | 14.8% | 3.0% | 6.3% | 3.8% |
| Back Pain | 10.0% | 10.6% | 9.5% | 10.2% |
| Nasopharyngitis | 6.8% | 8.0% | 14.1% | 13.4% |
| Dizziness | 6.2% | 3.3% | 6.8% | 5.2% |
| Hot flush | 16.9% | 4.3% | - | - |
| Dyspepsia | 9.2% | 4.1% | - | - |
| Diarrhoea | 8.7% | 5.3% | - | - |
| Influenza | 7.0% | 6.9% | - | - |
| Hypertension | 6.0% | 7.7% | - | - |
| Hypercalciuria | - | - | 11.3% | 6.7% |
| Headache | - | - | 7.6% | 6.5% |
| Upper respiratory tract infection | - | - | 7.0% | 5.6% |
| Pain in extremity | - | - | 6.0% | 5.2% |
| Constipation | - | - | 5.3% | 4.5% |
Trial register Calcitonin: 2 placebo-controlled trials; Teriparatide: 11. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Calcitonin side effects · Teriparatide side effects
LEGAL STATUS
Approval in each country read
| Country | Calcitonin | Teriparatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
5 registered trials include both
| NCT05366621 | Post-fracture Medication and Mortality COMPLETED · updated 2023-04-04 |
|---|---|
| NCT00414973 | A Study for Patients With Osteoporosis COMPLETED · updated 2009-10-28 |
| NCT00542984 | Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis COMPLETED · updated 2007-10-12 |
| NCT00543023 | A Study of the Treatment of Postmenopausal Women With Osteoporosis COMPLETED · updated 2007-10-12 |
| NCT00543218 | PTH Comparison in Post Menopausal Women COMPLETED · updated 2007-10-12 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.